AUGUSTA, Ga. – Drs. Claude Sportès, Frank Mott, and Shou-Ching Tang will assume leadership positions on Georgia Regents University Cancer Center’s Bone Marrow Transplant, Head and Neck and Breast Cancer multidisciplinary teams.
Sportès, a renowned physician, scientist and expert bone marrow transplant specialist, has been named Director of the GRU Cancer Center Bone Marrow and Stem Cell Transplant Program. He will also serve as Leader of the Transplant Translational Immunotherapy and Biology Initiative. He comes to the GRU Cancer Center after 20 years as a key physician and leader at National Cancer Institute’s Center for Cancer Research in Bethesda, MD., where he most recently served as Staff Clinician at the for the Experimental Transplantation and Immunology Branch.
Prior to joining NCI, Sportès was Senior Staff at the Bone Marrow Transplant program at the Henry Ford Hospital in Detroit, Mich. He also worked at Hôpital Saint-Louis in Paris on transplantation research under the direction of Professor Eliane Gluckman, who performed the world’s first umbilical cord blood stem cell transplantation.
Sportès recently served as the Principal Investigator of four NCI clinical trials and has been published 44 times. In 2010 he received an NCI Director Group Merit Award. Sportès received his medical degree from Pierre and Marie Curie University of Paris and completed a pediatric residency and a pediatric oncology fellowship at the University of Michigan.
“My motto for the Bone Marrow and Stem Cell Transplant Program at GRU will be ‘excellence in care, driven by compassion and driven by science,’” Sportès said. “I look forward to building on our core strengths as we transform and grow our transplant program.”
Mott will serve as Co-Leader of the Head and Neck Multidisciplinary Clinic, Co-Leader of the Head and Neck Interdisciplinary Translational Team, and Associate Director of the Hematology/Oncology Fellowship Training Program. He previously served as Chairman of the Hematology-Oncology department and Director of Thoracic Medical Oncology at Ochsner Medical Center in New Orleans, LA.
He has been published 45 times and his clinical interests include head and neck and thoracic malignancies. He has also researched targeted drug development and biomarker research in these fields.
An internationally recognized breast cancer treatment and research expert, Tang has been named Co-Leader of the Breast Cancer Multidisciplinary Team and the Breast Cancer Interdisciplinary Translational Research Team. He previously served as Adjunct Clinical Professor of Medicine at University of Minnesota and as a Clinical Oncologist with the Minnesota Cancer Specialists. He has also practiced with US Oncology in Minnesota and served as the Martha Macon Stimpson Endowed Chair in Medical Oncology at the Virginia Piper Cancer Institute and Scientific Advisor for the US Oncology Research and Breast Research Committee.
Tang has been instrumental in the development of groundbreaking clinical trials that have changed the rules and recommendations associated with breast cancer treatment.
Tang has several active grants and is well published with 77 peer reviewed articles and two books. He is is one of the founding members of the Breast Cancer International Research Group and served on its Scientific Advisory Board. He was also founding chair of the Atlantic Canada Oncology Group and founding President of the US-Chinese Anti-Cancer Association.
“I feel proud to be part of the GRU Cancer Center team and look forward to taking care of the breast cancer patients at there,” Tang said.
The GRU Cancer Center is a multi-disciplinary academic cancer center focused on both research and clinical treatment. Its patient-centered approach to treatment includes first-in-the-nation treatment protocols, an experimental therapeutics program that includes specialized clinics for Phase I trials and immunotherapy and a variety of ancillary programs – including music therapy and genetic counseling – designed with holistic healing in mind.